| Tumor Factors |
Overall (n = 395) |
Caucasian (n = 307) |
African American (n = 39) |
Hispanic (n = 10) |
Asian-Pacific Islander (n = 24) |
Unknown/ Others (n = 15) |
p value* |
| Histopathology |
|
|
|
|
|
|
0.419 |
| DCIS |
307 (77.7%) |
242 (78.8%) |
29 (74.4%) |
7 (70.0%) |
19 (79.2%) |
10 (66.7%) |
|
| DCIS with IDC |
70 (17.7%) |
52 (16.9%) |
6 (15.4%) |
2 (20.0%) |
5 (20.8%) |
5 (33.3%) |
|
| DCIS with LCIS |
18 (4.6%) |
13 (4.2%) |
4 (10.3%) |
1 (10.0%) |
0 (0.0%) |
0 (0.0%) |
|
| Tumor characteristics |
|
|
|
|
|
|
|
| Median tumor size (cm) |
1.0 |
1.0 |
0.2 |
0.1 |
0.1 |
0.1 |
0.861 |
| Multicentricity |
47 (11.9%) |
34 (11.1%) |
5 (12.8%) |
2 (20.0%) |
3 (12.5%) |
3 (20.0%) |
0.772 |
| Multifocality |
92 (23.3%) |
72 (23.5%) |
9 (23.1%) |
3 (30.0%) |
3 (12.5%) |
5 (33.3%) |
0.615 |
| High Grade |
140 (35.4%) |
107 (34.9%) |
16 (41.0%) |
3 (30.0%) |
10 (41.7%) |
4 (26.7%) |
0.931 |
| Comedonecrosis |
264 (66.8%) |
199 (64.8%) |
29 (74.4%) |
7 (70.0%) |
19 (79.2%) |
10 (66.7%) |
0.364 |
| Receptor status |
|
|
|
|
|
|
|
| ER positive |
235 (59.5%) |
182 (81.3%) |
21 (77.8%) |
9 (90.0%) |
12 (70.6%) |
11 (84.6%) |
0.737 |
| PR positive |
182 (46.1%) |
139 (62.1%) |
17 (63.0%) |
7 (70.0%) |
9 (52.9%) |
10 (79.6%) |
0.721 |
| HER-2/neu positive |
24 (6.1%) |
21 (50.0%) |
2 (50.0%) |
0 (0.0%) |
0 (0.0%) |
1 (25.0%) |
0.469 |
| USC/Van Nuys prognostic index |
|
|
|
|
|
|
<0.001 |
| Low score |
130 (32.9%) |
103 (33.6%) |
15 (38.5%) |
0 (0.0%) |
5 (20.8%) |
7 (46.7%) |
|
| Intermediate score |
264 (66.8%) |
204 (66.4%) |
24 (61.5%) |
10 (100%) |
19 (79.2%) |
7 (46.7%) |
|
| High score |
1 (0.3%) |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
1 (6.7%) |
|